Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2003

01-02-2003

A Phase I Clinical Trial of Spicamycin Derivative KRN5500 (NSC 650426) Using a Phase I Accelerated Titration “2B” Design

Authors: S.M. Gadgeel, R.R. Boinpally, L.K. Heilbrun, A. Wozniak, V. Jain, B. Redman, M. Zalupski, R. Wiegand, R. Parchment, P.M. LoRusso

Published in: Investigational New Drugs | Issue 1/2003

Login to get access
Metadata
Title
A Phase I Clinical Trial of Spicamycin Derivative KRN5500 (NSC 650426) Using a Phase I Accelerated Titration “2B” Design
Authors
S.M. Gadgeel
R.R. Boinpally
L.K. Heilbrun
A. Wozniak
V. Jain
B. Redman
M. Zalupski
R. Wiegand
R. Parchment
P.M. LoRusso
Publication date
01-02-2003
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 1/2003
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1022972427532

Other articles of this Issue 1/2003

Investigational New Drugs 1/2003 Go to the issue

OriginalPaper

Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma

OriginalPaper

A Phase I and Pharmacologic Study of Pyrazoloacridine and Cisplatin in Patients with Advanced Cancer

OriginalPaper

An Overview on the Antileukemic Potential of D-homo-aza- and Respective 17β-Acetamido-Steroidal Alkylating Esters

OriginalPaper

Discovery and Preclinical Antitumor Efficacy Evaluations of LY32262 and LY33169

OriginalPaper

Primary Tumor, Lung and Kidney Retention and Antimetastasis Effect of NAMI-A Following Different Routes of Administration

OriginalPaper

Effect of the Antitumor Drug Vinblastine on Nuclear βII-tubulin in Cultured Rat Kidney Mesangial Cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits